Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10274560 | 0.87 | — | — | |
| SCHEMBL890513 | 0.87 | — | — | |
| Water SCHEMBL1358117 | 0.84 | MAPT (0.44) | SLC22A16MAPTTSHR | |
| SCHEMBL16405718 | 0.77 | MAPT (0.44) | SLC22A16MAPTTSHR | |
| Formic Acid SCHEMBL11662526 | 0.75 | MAPT (0.43) | SLC22A16MAPTTSHR | |
| Water SCHEMBL11452058 | 0.75 | TSHR (0.43) | SLC22A16MAPTTSHR | |
| Formic Acid SCHEMBL11662523 | 0.73 | SLC22A16 (0.46) | SLC22A16MAPTTSHR | |
| Prolonium SCHEMBL1649967 | 0.71 | MAPT (0.52) | SLC22A16MAPTTSHR | |
| SCHEMBL17430801 | 0.70 | MAPT (0.37) | SLC22A16MAPTTSHR | |
| SCHEMBL12192711 | 0.69 | PSMD14 (0.35) | SLC22A16MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154550-B2 | Treatment for neurodegeneration | THE UNIVERSITY OF BIRMINGHAM (GB) | 2021-10-26 | — | — | US | disclosed |
| EP-2900236-B2 | TREATMENT OF WOLFRAM SYNDROME-RELATED NEURODEGENERATION | UNIV BIRMINGHAM (GB) | 2021-09-29 | — | — | EP | disclosed |
| EP-2900236-B1 | TREATMENT OF WOLFRAM SYNDROME-RELATED NEURODEGENERATION | UNIV BIRMINGHAM (GB) | 2019-01-16 | — | — | EP | disclosed |
| US-20150246037-A1 | TREATMENT FOR NEURODEGENERATION | THE UNIVERSITY OF BIRMINGHAM (GB) | 2015-09-03 | — | — | US | disclosed |
| US-6353015-B1 | INDOLE DERIVATIVES FOR NERVOUS SYSTEM DISORDERS | ST. ELIZABETH'S MEDICAL CENTER | 2002-03-05 | — | — | US | disclosed |
| WO-2000012045-A2 | METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | ST. ELIZABETH'S MEDICAL CENTER OF BOSTON, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
| EP-0625196-A1 | NEUROTROPHIC FACTOR | HOUSTON BIOTECHNOLOGY INCORPORATED (US) | 1994-11-23 | — | — | EP | disclosed |
| WO-1994012634-A1 | NEUROTROPHIC FACTOR | HOUSTON BIOTECHNOLOGY INCORPORATED (US) | 1994-06-09 | — | — | WO | disclosed |
| EP-0178743-B1 | NOVEL TRITIUM LABELLED N-MUSTARD TYPE COMPOUNDS AND A PROCESS FOR THEIR PRODUCTION | UNIVERSITY OF PITTSBURGH (US) | 1990-05-23 | — | — | EP | disclosed |
| US-4795627-A | AZIRIDINIUM ANALOG USED TO EVALUATE THE MECHANISM OF NEUROTRANSMITTER REGULATION | UNIVERSITY OF PITTSBURGH (US) | 1989-01-03 | — | — | US | disclosed |